Evidence map›GLP-1 receptor agonists × adverse events & safety›PMID 25880805›Full record

ArticleBMC endocrine disorders2015

The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.

Hassan Kahal, Ahmed Aburima, Tamas Ungvari, Alan S Rigby, Anne M Coady, Rebecca V Vince, Ramzi A Ajjan, Eric S Kilpatrick, Khalid M Naseem, Stephen L Atkin

Registry-linked trialOpen access · goldFull text readControlled Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC endocrine disorders, 2015. The graph read 2 numbers from its abstract, feeding 1 cell of the map: it finds no clear difference in 1. It is linked to trial NCT03352869 (Research of Exenatide for Management of Reproductive and Metabolic Dysfunction in Overweight/Obese PCOS Patients With Impaired Glucose Regulation), which is not on this map. Cited by 35 papers, 5 of them syntheses that pooled it.

2numbers the graph read from it
1cell of the map it votes in
35citing papers in PubMed, 5 pooled it
5.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

← favours the treatmentfavours the comparator →
0.260 · no effect
Adverse events & safetyno clear difference · against placebo · ascvd, t2dfeeds one cell of the map
Δ 0.26P = 0.41
Basal platelet P-selectin expression was significantly reduced at six months in controls -0.17 ± 0.26 but not PCOS -0.12 ± 0.28; between groups difference, 95% confidence interval = -0.14 - 0.26, P = 0.41.
FeedsGLP-1 receptor agonists×adverse events & safety

Read, but not usablea number the graph found but could not read as for or against

Adverse events & safetydirection of benefit for this outcome is not defined · against placebo · ascvd, t2dfeeds one cell of the map
reduced -4.20P < 0.01
Following 6 months of treatment with liraglutide 1.8 mg od body weight was reduced by 3.0 ± 4.2 (P < 0.01) and 3.8 ± 3.4 kg (P < 0.01); BMI by 1.0 ± 1.5 (P = 0.01) and 1.4 ± 1.2 kg/m2 (P < 0.01); while average heart rate increased by 3 ± 7 (P = 0.051) and 4 ± 7 beats per minute (bpm) (P = 0.02) in the PCOS and control groups, respectively.
FeedsGLP-1 receptor agonists×adverse events & safety

clause the extractor read what became the number

2 · Its place on the map

Where it lands on the map

Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.

supports the treatmentfavours the comparatorno clear differenceread, but no usable result
3 · What it changes

What it adds to each cell

For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.

GLP-1 receptor agonists×adverse events & safety

InconclusiveOpen on the map →What to test next →

40 readable studies in this cell: 47 favour the treatment, 14 find no difference, 2 favour the comparator.

Belief with this paper
0.02contested · 1 family supports, 41 contradict · against placebo
Without it
0.02This paper does not move the number.
← favours the treatmentfavours the comparator →
0 · no effect
This paper · 2015
Δ 0.26
NCT017204463,297 enrolled · 2013
Δ -0.66-0.80 to -0.52
NCT036893742,274 enrolled · 2018
Δ -0.29-0.38 to -0.20
NCT013360231,663 enrolled · 2011
Treatment contrast -0.64-0.75 to -0.53
NCT040178321,441 enrolled · 2019
Δ -0.20-0.30 to -0.10
NCT018365231,398 enrolled · 2013
Δ -0.20-0.32 to -0.07
NCT019301881,231 enrolled · 2013
Δ -1.06-1.21 to -0.91
NCT007344741,202 enrolled · 2008
Δ -0.71-0.87 to -0.55
NCT008389031,049 enrolled · 2009
Δ -0.91-1.16 to -0.65
NCT009606611,036 enrolled · 2009
Δ -0.04-0.18 to 0.11
NCT050350821,018 enrolled · 2021
Δ -0.24-0.44 to -0.04
NCT01064687978 enrolled · 2010
Δ -1.05-1.22 to -0.88
NCT01117350978 enrolled · 2010
Δ 2.54-3.88 to 8.93
4 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03352869 phase4completedstarted 2017, after this paper: background citation

Research of Exenatide for Management of Reproductive and Metabolic Dysfunction in Overweight/Obese PCOS Patients With Impaired Glucose Regulation

Ran2017Enrolled183Registered outcomes4Posted comparisons0ConditionsDisorder of Glucose Regulation, Overweight and Obesity, Polycystic Ovary SyndromeArmsexenatide, Metformin
PMID 24256515PMID 24362411PMID 28143456PMID 25330463PMID 18460557PMID 25726702other papers from this trial
Open the trial in the graph
5 · Its place in the literature

Who cites it

35 citing papers in PubMed, 5 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Multidisciplinary Therapy to Target Obesity and Its Complications in Adult Population: A Narrative Review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
6 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

7 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Hassan KahalAcademic Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK. hassan.kahal@yahoo.co.uk.
Ahmed AburimaCentre for Cardiovascular and Metabolic Research, Hull York Medical School, Hull, UK. A.Aburima@hull.ac.uk.
Tamas UngvariDepartment of Cardiology, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK. drungvaritamas@yahoo.com.
Alan S RigbyCentre for Cardiovascular and Metabolic Research, Hull York Medical School, Hull, UK. asr1960@hotmail.com.
Anne M CoadyDepartment of Radiology, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK. anne.coady@hey.nhs.uk.
Rebecca V VinceDepartment of Sport, Exercise and Health Science, University of Hull, Hull, UK. rebecca.vince@hull.ac.uk.
Ramzi A AjjanDivision of Cardiovascular and Diabetes Research, Leeds Institute for Genetics, Health and Therapeutics, University of Leeds, Multidisciplinary Cardiovascular Research Centre, Leeds, UK. R.Ajjan@leeds.ac.uk.
Eric S KilpatrickClinical Biochemistry, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK. Eric.Kilpatrick@hey.nhs.uk.
Khalid M NaseemCentre for Cardiovascular and Metabolic Research, Hull York Medical School, Hull, UK. Khalid.Naseem@hyms.ac.uk.
Stephen L AtkinWeill Cornell Medical College Qatar, PO Box 24144, Doha, Qatar. sla2002@qatar-med.cornell.edu.
Hull York Medical School · GBHull and East Yorkshire Hospitals NHS Trust · GBUniversity of Hull · GBUniversity of Leeds · GBWeill Cornell Medical College in Qatar · QA

Funding

British Heart Foundation FS/10/020/28242British Heart Foundation PG/12/49/29441
8 · The paper itself

Abstract

The marked sentences are the ones the graph read a number from.

backgroundPolycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular (CV) risk markers. In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.

methodsCarotid intima-media wall thickness (cIMT) was measured by B-mode ultrasonography, platelet function by flow cytometry, clot structure/lysis by turbidimetric assays and endothelial function by ELISA and post-ischaemic reactive hyperemia (RHI). Data presented as mean change (6-month - baseline) ± standard deviation.

resultsNineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups. Twenty five (69.4%) participants completed the study (13 PCOS, 12 controls). At six months, weight was significantly reduced by 3.0 ± 4.2 and 3.8 ± 3.4 kg in the PCOS and control groups, respectively; with no significant difference between the two groups, P = 0.56. Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline. Basal platelet P-selectin expression was significantly reduced at six months in controls -0.17 ± 0.26 but not PCOS -0.12 ± 0.28; between groups difference, 95% confidence interval = -0.14 - 0.26, P = 0.41. No significant changes were noted in cIMT or RHI.

conclusionsSix months treatment with liraglutide (1.8 mg od) equally affected young obese women with PCOS and controls. In both groups, liraglutide treatment was associated with 3-4% weight loss and significant reduction in atherothrombosis markers including inflammation, endothelial function and clotting. Our data support the use of liraglutide as weight loss medication in simple obesity and suggest a potential beneficial effect on platelet function and atherothrombotic risk at 6 months of treatment.

trial registrationClinical trial reg. no. ISRCTN48560305. Date of registration 22/05/2012.

Indexed as

AdolescentAdultBlood PlateletsCardiovascular DiseasesCarotid Intima-Media ThicknessFemaleFibrinolysisGlucagon-Like Peptide 1HumansHypoglycemic AgentsInsulin ResistanceLiraglutideMiddle AgedPolycystic Ovary SyndromeRisk FactorsYoung AdultGlucagon-Like Peptide 1Hypoglycemic AgentsLiraglutide

Identifiers

PMID25880805
PMCPMC4389314
OpenAlexW1992338711

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.